Sanofi, GSK variant-specific COVID shot found effective against Omicron

Published by

By Natalie Grover PARIS/LONDON (Reuters) – Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday. The so-called bivalent vaccine targets the Beta variant – first identified in South Africa – as well as the original Wuhan strain of the virus. In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant. When used in people who previously h…

Read More

Leave a Reply